ado-trastuzumab emtansine for injection

ado-trastuzumab emtansine for injection,
for intravenous use Initial U.S. Approval: {YYYY}

Kadcyla (trastuzumab emtansine) is a cancer medicine that is used to treat advanced or metastatic HER2-positive breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane.

Facts about ado-trastuzumab emtansine for injection

Disease Indications-Breast Cancer
Manufacturer-Genentech, Inc
Usage-Intravenous
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “ado-trastuzumab emtansine for injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query For ado-trastuzumab emtansine for injection

Description

Approved accessible "ado-trastuzumab emtansine for injection"

Ado-Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death.

How can 1 go about obtaining ado-trastuzumab emtansine for injection?

To access ado-trastuzumab emtansine for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: {YYYY}

References

Full prescribing information [FDA]: Kadcyla (trastuzumab emtansine) [PDF], Genentech, May 2019.
Kadcyla Breastcancer.org
Australian Product Information [TGA]: Kadcyla (trastuzumab emtansine) [PDF], Roche, Sep 2019.
U.S. Food and Drug Administration. FDA approves ado-trastuzumab emtansine for early breast cancer. 06/05/2019 (last update: 06/05/2019), cited on 10/03/2020.
Summary of Product Characteristics [EMA]: Kadcyla (trastuzumab emtansine) [PDF], Roche, Jan 2020.

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

ado-trastuzumab emtansine for injection